Pituitary Tumors and Pituitary Disorders

The pituitary gland, a pea-sized structure at the base of the brain, governs hormone production across the entire endocrine system — making disorders of this gland among the most consequential in all of medicine. Pituitary tumors affect an estimated 1 in 5 people at some point in their lifetime based on autopsy and MRI incidence data, though the majority remain clinically silent. This page covers the classification of pituitary tumors, the hormonal mechanisms driving disease, common clinical presentations, and the frameworks physicians use to guide diagnosis and treatment decisions.

Definition and scope

A pituitary disorder is any condition that disrupts the normal structure or secretory function of the pituitary gland. The two anatomical subdivisions — the anterior pituitary (adenohypophysis) and the posterior pituitary (neurohypophysis) — each produce or regulate distinct hormones, so disorders are classified both by location and by functional effect.

Pituitary tumors are the most common structural pituitary disorder. According to the National Cancer Institute, pituitary adenomas represent approximately 15% of all primary intracranial neoplasms. The overwhelming majority are benign, slow-growing adenomas rather than carcinomas; pituitary carcinoma is rare, defined by the World Health Organization (WHO) only when metastatic spread is confirmed.

Tumors are classified along two primary axes:

  1. Size — Microadenomas measure less than 10 mm in greatest diameter; macroadenomas measure 10 mm or greater. Giant adenomas exceed 40 mm and carry higher surgical risk.
  2. Functional status — Functioning (secreting) adenomas overproduce one or more hormones; non-functioning adenomas cause disease primarily through mass effect rather than hormone excess.

Beyond adenomas, pituitary disorders include craniopharyngiomas, Rathke's cleft cysts, hypophysitis (inflammation of the pituitary), and hypopituitarism resulting from radiation, surgery, trauma, or infiltrative disease. The American Association of Neurological Surgeons (AANS) recognizes pituitary tumors as one of the most surgically accessible brain lesions, with transsphenoidal resection as the primary operative approach.

For broader context on the regulatory and clinical infrastructure governing endocrine disease management, see the regulatory context for endocrinology page on this site.

How it works

The anterior pituitary secretes six major hormones — growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) — under the control of hypothalamic releasing and inhibiting factors. Functioning adenomas arise from a monoclonal expansion of a single secretory cell type, resulting in autonomous, feedback-resistant hormone overproduction.

The posterior pituitary stores and releases antidiuretic hormone (ADH, also called vasopressin) and oxytocin, both synthesized in the hypothalamus. Posterior pituitary pathology — most notably central diabetes insipidus — results from deficient ADH secretion, causing urine volumes that can exceed 10–15 liters per day in severe cases.

Hormone excess follows cell-of-origin patterns:

Mass effect from any adenoma can compress the optic chiasm (producing bitemporal hemianopia), impinge on the cavernous sinuses, or destroy adjacent normal pituitary tissue, causing hypopituitarism with deficits across one or more of the six anterior hormones.

Diagnosis relies on a structured pituitary hormone panel combined with pituitary MRI, which allows simultaneous anatomical and biochemical characterization. The MRI with gadolinium contrast remains the gold-standard imaging modality per American College of Radiology (ACR) protocols.

Common scenarios

Three presentations dominate clinical pituitary practice:

Prolactinoma — The most frequently encountered pituitary tumor type. Elevated prolactin suppresses GnRH, producing amenorrhea and galactorrhea in women and hypogonadism in men. Dopamine agonists (cabergoline, bromocriptine) normalize prolactin in more than 80% of patients and can shrink tumor volume, making surgery a second-line option for most cases.

Acromegaly — Caused by GH excess from a somatotroph adenoma, acromegaly carries a mortality risk approximately 2-fold above the general population if untreated, primarily from cardiovascular and respiratory complications (Endocrine Society Clinical Practice Guidelines, Acromegaly, 2014). Diagnosis requires a failed GH suppression on oral glucose tolerance testing plus elevated insulin-like growth factor-1 (IGF-1).

Non-functioning macroadenoma — Often detected incidentally on imaging performed for unrelated reasons (a "pituitary incidentaloma"). Management decisions depend on tumor size, proximity to the optic chiasm, and the presence of hypopituitarism. Tumors within 3–5 mm of the optic chiasm typically prompt surgical referral.

Hypopituitarism — whether caused by a tumor, surgery, radiation, or autoimmune hypophysitis — requires individualized hormone replacement for adrenal and pituitary deficiencies, with adrenocortical insufficiency receiving the highest replacement priority because of its life-threatening potential.

Decision boundaries

Physicians navigate pituitary disorders using a framework built around four questions:

  1. Is the tumor secreting? Functional status drives medical therapy choices before surgical options are considered.
  2. Is there mass effect threatening vision or adjacent structures? Chiasmal compression, cavernous sinus invasion, or hydrocephalus shifts the decision toward urgent surgical decompression.
  3. Is the patient hormonally deficient? Even small tumors can destroy normal gonadotroph or somatotroph cell populations; baseline adrenal function testing and a full hormone panel are mandatory before any intervention.
  4. Is watchful waiting appropriate? Microadenomas without functional excess or structural risk are managed with serial MRI at 6–12 month intervals under protocols outlined by the Pituitary Society's consensus guidelines.

The contrast between functioning microadenomas and non-functioning macroadenomas illustrates the core decision asymmetry: a 6 mm ACTH-secreting adenoma demands aggressive pursuit (biochemical cure requires surgical resection achieving less than 5 µg/dL post-operative serum cortisol per Endocrine Society thresholds), while a 12 mm non-functioning adenoma without chiasmal contact may be observed.

Radiation — stereotactic radiosurgery (Gamma Knife) or fractionated radiotherapy — occupies a third-line role, used when surgery fails to achieve remission and medical therapy is insufficient or not tolerated. The American Society for Radiation Oncology (ASTRO) publishes evidence-based guidelines governing dose parameters for pituitary targets.

Multidisciplinary management involving endocrinology, neurosurgery, and ophthalmology is the standard of care at academic centers. For patients encountering the broader landscape of endocrine conditions and specialist roles, the endocrinology authority site index provides a structured overview of condition-specific and specialty-specific resources.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)